Table: Eisai -9-MTH group results (IFRS)
Feb 9 (Reuters)-
Eisai Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2025 Dec 31, 2024 Mar 31, 2026
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 619.95 601.16 790.00
(+3.1 pct) (+9.1 pct) (+0.1 pct)
Operating 54.45 55.40 54.50
(-1.7 pct) (+47.6 pct) (+0.2 pct)
Pretax 58.94 61.09 59.00
(-3.5 pct) (+39.8 pct) (-3.4 pct)
Net 41.81 45.48 41.50
(-8.1 pct) (+56.3 pct) (-10.6 pct)
EPS Basic 148.31 yen 160.14 yen 147.20 yen
Ann Div 160.00 yen 160.00 yen
-Q2 Div 80.00 yen 80.00 yen
-Q4 Div 80.00 yen 80.00 yen
NOTE - Eisai Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4523.T
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China